Clinical operations
How to Document Sleep Changes in Oncology Trials
How oncology sites and monitors document sleep changes, reconcile medication timelines and give investigators the context to assess adverse events.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
When a participant reports new or worsening trouble sleeping, record what sleep usually looks like for that person, when it changed and what they were taking around that time. This gives the investigator context to assess the event and the sponsor a way to compare reports across sites.
The National Cancer Institute identifies pain, anxiety, medication and other treatment factors as possible contributors to sleep disruption in people with cancer. Dexamethasone is used in some regimens to prevent nausea and vomiting after chemotherapy, and its prescribing information lists insomnia. The label gives the study team a reason to check the medication timeline. The investigator considers the full clinical picture when assessing an individual event. [1, 2, 3]
In a 2006 questionnaire study, 45% of 60 patients taking oral dexamethasone after moderately emetogenic chemotherapy reported moderate to severe insomnia in the following week. The single-group design left the contributions of dexamethasone, chemotherapy and other factors unresolved. [3]
What this means for trial teams
Start with the participant’s description. Ask how sleep has changed, if at all. Record whether the difficulty is falling asleep, staying asleep or staying alert during the day. Capture when it began, how long it lasted and how it affected daily activities. Work schedules and caregiving can change what a usual sleep period looks like.
Reconcile the medication timeline. Compare symptom onset with study treatment, supportive medications, outside prescriptions and nonprescription products. Check relevant start and stop dates and changes in dose or timing against the treatment cycle. The clinical research associate (CRA) can review discrepancies under the monitoring plan, including when a medication was listed but its timing was unclear.
Give each decision an owner. The investigator assesses severity, seriousness and possible causes. The site follows the protocol’s safety collection and reporting requirements while the assessment is underway. The CRA verifies the documentation and escalates gaps through the study’s process. The sponsor can review recurring reports for a common treatment schedule or differences in how sites capture the event. This helps the sponsor decide where to investigate. [4]
Plan structured sleep measurement when it serves a study objective. FDA’s oncology guidance recommends collecting patient reports of symptomatic adverse events and other aspects of the treatment experience. When sleep is a meaningful outcome, choose a measure suited to the research question, specify the assessment windows and provide instructions in the languages the study supports. Consider the time and access participants need to complete the assessment. Continue to follow the protocol’s safety-reporting process alongside patient-reported outcome collection. [5]
At Lampgen Clinical Research, we use scenarios like this to define what oncology monitoring coverage needs to include. A monitor should be able to explain what evidence is missing, who owns the assessment and how to verify follow-up. That gives the study team a clearer view of what patients experience across the full regimen.
Sources
- National Cancer Institute • Sleep Disorders (PDQ), health professional version
- DailyMed • Dexamethasone prescribing information
- Vardy et al. • Dexamethasone symptom questionnaire study, British Journal of Cancer, 2006
- FDA • E6(R3) Good Clinical Practice, section 2.7.2 on safety reporting
- FDA • Core Patient-Reported Outcomes in Cancer Clinical Trials
- Related Lampgen insight • Making oncology patient-reported outcomes usable
- Related Lampgen insight • How to evaluate an oncology CRA